A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Morbus Hodgkin

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

CD (Cluster of Differentiation)

CD20

Cereblon (E3 Ubiquitin Ligase)

Phase I/II

CC-220-NHL-001

Zweitlinie

<div>An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir</div><div>in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</div><div>(NAVAL-1)</div>

Phase II

NAVAL-1

Comprehensive Cancer Center Mainfranken

Studien des CCC Mainfranken